Hepatorenal Syndrome Treatment Market – Global Industry Analysis and Forecast (2022-2029)

Hepatorenal Syndrome Treatment Market is expected to reach US$ 13.73 Bn. at a CAGR of 13.12% during the forecast period 2029.

Hepatorenal Syndrome Treatment Market Overview:

Hepatorenal syndrome (HRS) is a life-threatening medical disorder in which kidney function rapidly deteriorates in those who have cirrhosis or fulminant liver failure. Unless a liver transplant is performed, HRS is usually deadly, while other therapies, such as dialysis, might slow the progression of the disease. Global Hepatorenal Syndrome Treatment marketTo know about the Research Methodology:- Request Free Sample Report

 Hepatorenal Syndrome Treatment Market Dynamics:

Rising prevalence of Hepatorenal Syndrome is the major factor contributing to the market growth. The rise in the number of individuals with liver injury or cirrhosis is the key driver of the Global Hepatorenal Syndrome Treatment market. According to data from the Centres for Disease Control and Prevention, 4.5 million persons in the United States were diagnosed with chronic liver disease in 2018. Patients with Hepatorenal syndrome typically have a wide range of symptoms, including abdominal pain, weakness, and discomfort. Severe symptoms include a jaundice-like yellowing of the skin and eyes, an enlarged liver and spleen, and fluid collection in the abdomen known as ascites. To improve the Hepatorenal syndrome treatment market, increased illness knowledge and patient support initiatives are needed. Governments in both rich and developing nations run public awareness efforts to urge people to seek early diagnosis of kidney and liver illness, lowering death and morbidity rates. Increasing the number of fast-track and orphan medication designations also helps to boost the market growth. BioVie Inc. announced in November 2018 that the FDA had granted its Terlipressin medication Orphan Drug Designation for the treatment of hepatorenal syndrome (HRS). Another element driving market growth is the rising consumption of harmful foods and beverages, such as alcohol. The rising elderly population, as well as the occurrence of disease, boosts the market growth. Albumin's widespread use is also aiding the market's growth. Healthcare professionals propose a combination of albumin combined with antibiotics as a cost-effective treatment for HRS with cirrhosis. The treatment of HRS, on the other hand, has been shown to put an individual under extreme financial stress, hence impeding the market growth. The report has profiled fifteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Hepatorenal Syndrome Treatment Market Segment Analysis:

The Hepatorenal Syndrome Treatment Market is segmented on the basis of Treatment and End-Users. Based on Treatment, the therapeutics segment is expected to grow at a CAGR of XX% during the forecast period. Patients prefer taking pharmaceuticals over having procedures, thus the therapeutics segment is likely to increase at a faster rate. Increasing the number of medications with fast track and orphan designations is also helping to grow the market. Several pharmaceuticals have been designated as orphan pharmaceuticals, which accelerate their approval process, and this could be a driver driving treatment growth. The FDA granted Orphan Medication designation to BioVie Inc.'s Terlipressin drug for the treatment of hepatorenal syndrome in November 2018. Orphan medication status entitles manufacturers to a variety of benefits, including tax rebates for eligible clinical trials and seven years of commercial exclusivity following regulatory approval. This will drive the global market during the forecast period.

Hepatorenal Syndrome Treatment Market Regional Insights:

North America dominates the global market. Throughout the projected period, North America is likely to lead the global market. Factors such as the existence of important companies developed healthcare infrastructure, and the growing prevalence of severe liver disease and cirrhosis are some of the important factors responsible for the market's big share. Furthermore, favorable government efforts and an increase in the number of research partnerships are projected to propel the market forward. Due to favorable healthcare legislation, a large number of patients, and a developed healthcare market, the United States have the largest share in this region. Cirrhosis affects one in every 400 adults in the United States, according to the US Department of Health and Human Services. According to statistics, the region's market growth is boosted by an expanding patient pool and rising disposable income. The report also helps in understanding Global Hepatorenal Syndrome Treatment Market dynamics, structure by analyzing the market segments and project the Global Hepatorenal Syndrome Treatment Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Hepatorenal Syndrome Treatment Market make the report investor’s guide.

Hepatorenal Syndrome Treatment Market Scope: Inquire before buying

Global Hepatorenal Syndrome Treatment Market
Report Coverage Details
Base Year: 2021 Forecast Period: 2022-2029
Historical Data: 2017 to 2021 Market Size in 2021: US$ 5.12 Bn.
Forecast Period 2022 to 2029 CAGR: 13.12% Market Size in 2029: US$ 13.73 Bn.
Segments Covered: by Treatment • Therapeutics • Liver Transplantation • Renal Replacement Therapy • Other Treatments
by End-users • Hospitals • Ambulatory Surgical Centers • Academic and Research Institutes • Others

Hepatorenal Syndrome Treatment Market, by Region:

• North America • Europe • South America • MEA • APAC

Hepatorenal Syndrome Treatment Market, Key players:

• Cumberland Pharmaceuticals, Inc. • Orphan Therapeutics, LLC. • BioVie Inc. • Mallinckrodt Pharmaceuticals • Ikaria Inc. • ESP Pharma Inc. • Edwards Lifesciences Corporation • Becton, Dickinson and Company • Fuji Systems Corp. • Johnson & Johnson Co. • New Medicon Pharma Lab • La Jolla Pharmaceutical Company • Noorik Biopharmaceuticals • PharmaIN Corp • Hikma Pharmaceuticals plc Frequently Asked Questions: 1. Which region has the largest share in Global Hepatorenal Syndrome Treatment Market? Ans: North America region holds the highest share in 2021. 2. What is the growth rate of Global Hepatorenal Syndrome Treatment Market? Ans: The Global Hepatorenal Syndrome Treatment Market is growing at a CAGR of 13.12% during forecasting period 2022-2029. 3. What is scope of the Global Hepatorenal Syndrome Treatment market report? Ans: Global Hepatorenal Syndrome Treatment Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Hepatorenal Syndrome Treatment market? Ans: The important key players in the Global Hepatorenal Syndrome Treatment Market are – Cumberland Pharmaceuticals, Inc., Orphan Therapeutics, LLC., BioVie Inc., Mallinckrodt Pharmaceuticals, Ikaria Inc., ESP Pharma Inc., Edwards Lifesciences Corporation, Becton, Dickinson and Company, Fuji Systems Corp., Johnson & Johnson Co., New Medicon Pharma Lab, La Jolla Pharmaceutical Company, Noorik Biopharmaceuticals, PharmaIN Corp, Hikma Pharmaceuticals plc, and. 5. What is the study period of this market? Ans: The Global Hepatorenal Syndrome Treatment Market is studied from 2021 to 2029.
1. Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Hepatorenal Syndrome Treatment Market Size, by Market Value (US$ Mn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2021 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Hepatorenal Syndrome Treatment Market 3.4. Geographical Snapshot of the Hepatorenal Syndrome Treatment Market, By Manufacturer share 4. Global Hepatorenal Syndrome Treatment Market Overview, 2021-2029 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porters Five Forces Analysis 4.1.6.1. Threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. Threat of Substitute Products 4.1.6.5. Intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Global Hepatorenal Syndrome Treatment Market 5. Supply Side and Demand Side Indicators 6. Global Hepatorenal Syndrome Treatment Market Analysis and Forecast, 2021-2029 6.1. Global Hepatorenal Syndrome Treatment Market Size & Y-o-Y Growth Analysis. 7. Global Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 7.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 7.1.1. Therapeutics 7.1.2. Liver Transplantation 7.1.3. Renal Replacement Therapy 7.1.4. Other Treatments 7.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 7.2.1. Hospitals 7.2.2. Ambulatory Surgical Centers 7.2.3. Academic and Research Institutes 7.2.4. Others 8. Global Hepatorenal Syndrome Treatment Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2021-2029 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. North America Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 9.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 9.1.1. Therapeutics 9.1.2. Liver Transplantation 9.1.3. Renal Replacement Therapy 9.1.4. Other Treatments 9.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 9.2.1. Hospitals 9.2.2. Ambulatory Surgical Centers 9.2.3. Academic and Research Institutes 9.2.4. Others 10. North America Hepatorenal Syndrome Treatment Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast By Country, 2021-2029 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 11.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 11.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 12. Canada Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 12.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 12.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 13. Mexico Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 13.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 13.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 14. Europe Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 14.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 14.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 15. Europe Hepatorenal Syndrome Treatment Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast By Country, 2021-2029 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K. Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 16.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 16.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 17. France Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 17.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 17.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 18. Germany Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 18.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 18.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 19. Italy Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 19.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 19.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 20. Spain Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 20.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 20.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 21. Sweden Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 21.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 21.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 22. CIS Countries Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 22.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 22.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 23. Rest of Europe Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 23.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 23.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 24. Asia Pacific Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 24.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 24.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 25. Asia Pacific Hepatorenal Syndrome Treatment Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates & Forecast By Country, 2021-2029 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 26.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 26.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 27. India Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 27.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 27.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 28. Japan Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 28.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 28.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 29. South Korea Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 29.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 29.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 30. Australia Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 30.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 30.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 31. ASEAN Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 31.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 31.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 32. Rest of Asia Pacific Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 32.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 32.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 33. Middle East Africa Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 33.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 33.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 34. Middle East Africa Hepatorenal Syndrome Treatment Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2021-2029 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 35.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 35.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 36. GCC Countries Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 36.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 36.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 37. Egypt Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 37.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 37.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 38. Nigeria Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 38.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 38.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 39. Rest of ME&A Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 39.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 39.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 40. South America Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 40.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 40.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 41. South America Hepatorenal Syndrome Treatment Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2021-2029 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 42.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 42.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 43. Argentina Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 43.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 43.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 44. Rest of South America Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2021-2029 44.1. Market Size (Value) Estimates & Forecast By Treatment, 2021-2029 44.2. Market Size (Value) Estimates & Forecast By End users, 2021-2029 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Global Hepatorenal Syndrome Treatment Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Applications and R&D Investment 45.2.2. New Product Launches and Product Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements 45.3. Company Profile : Key Players 45.3.1. Cumberland Pharmaceuticals, Inc. 45.3.1.1. Company Overview 45.3.1.2. Financial Overview 45.3.1.3. Geographic Footprint 45.3.1.4. Product Portfolio 45.3.1.5. Business Strategy 45.3.1.6. Recent Developments 45.3.2. Orphan Therapeutics, LLC. 45.3.3. BioVie Inc. 45.3.4. Mallinckrodt Pharmaceuticals 45.3.5. Ikaria Inc. 45.3.6. ESP Pharma Inc. 45.3.7. Edwards Lifesciences Corporation 45.3.8. Becton, Dickinson and Company 45.3.9. Fuji Systems Corp. 45.3.10. Johnson & Johnson Co. 45.3.11. New Medicon Pharma Lab 45.3.12. La Jolla Pharmaceutical Company 45.3.13. Noorik Biopharmaceuticals 45.3.14. PharmaIN Corp 45.3.15. Hikma Pharmaceuticals plc 46. Primary Key Insights

About This Report

Report ID 105652
Category Healthcare
Published Date Oct 2022
Updated Date
Contact Us